A Phase 2 interventional study of Testosterone cypionate and Placebo in Stress Urinary Incontinence and Menopause, sponsored by Brigham and Women's Hospital. Active, not recruiting at 1 site in United States. Open to female participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 190 studies in Urinary Incontinence, Stress with a site in United States — 28 open to participants now, 41 under way, 4 of them phase 3. Urinary Incontinence, Stress · United States.
Among the 190 studies in Urinary Incontinence, Stress with a site in United States, this one is the 129th largest by planned enrollment of the 164 interventional ones that give a count, is one of 13 that started in 2025, is one of 12 in phase 2, reaches primary completion later than 16 of the 40 other live ones, and was the 164th registered.
655 studies on the registry are indexed under Urinary Incontinence, Stress; 123 are open to participants now.
Browse Urinary Incontinence, Stress studies →28 of the 190 studies in Urinary Incontinence, Stress with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada
Ages 18+ · Women only
University of Miami · Sites in United States
Ages 18+ · Women only
Mayo Clinic · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Eli Lilly and Company · Sites in United States, Canada, China and 6 more countries
Ages 18+ · Women only
Ohio State University · Sites in United States
Ages 18–50 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 76 Urinary Incontinence, Stress studies recruiting now, 43 (57%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.
This study: 60 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
190 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 18 · Phase 3 24 · Phase 4 15
First in 2001; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 68 across 510 interventional studies indexed under Urinary Incontinence, Stress.
Median enrollment 99 across the 164 interventional studies, 98 across the 26 observational. Of the 129 that completed or were terminated, 56 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 190 have an industry lead sponsor. The 10 most frequent:
Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.
Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
Brigham and Women's Hospital has 1 study filed under Urinary Incontinence, Stress — fewer than ten, so there is no comparison to draw.
9 of the studies in Urinary Incontinence, Stress with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06968741UroMems SASA Study to Assess the Safety and Effectiveness of the UrOActive® Artificial Urinary sPHincter (AUS) | 2026-12 |
| NCT06111209Brigham and Women's HospitalThe Anabolic Effect of Testosterone on Pelvic Floor Muscles | 2026-12-31 |
| NCT06369922University of RochesterTENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence. | 2027-01-31 |
| NCT06706362Ohio State UniversityAssessing the Utility of Prophylactic Antibiotics at Time of Urethral Bulking Using Bulkamid (Bulkamid Study) | 2027-04-15 |
| NCT07008898University of Alabama at BirminghamSequence of Midurethral Sling Placement During Robotic Sacrocolpopexy | 2027-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 190 studies in Urinary Incontinence, Stress with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Stress urinary incontinence is the most common female pelvic floor disorder encountered in clinical practice with significant negative impact on quality of life. The prevalence of urinary incontinence increases with aging, and weakness of the pelvic floor muscles contributes to the development of stress urinary incontinence. Given that androgen receptors are expressed throughout the pelvic floor, the anabolic effects of androgens on pelvic floor muscles may provide a therapeutic option in women with stress urinary incontinence. The investigators are conducting a randomized, double-blind, placebo-controlled proof-of-concept trial in older postmenopausal women with stress urinary incontinence to assess whether testosterone therapy can increase pelvic floor muscles and improve urinary function.
The investigators are conducting a 12-week double-blind, randomized-controlled, proof-of-concept pilot trial to determine the anabolic effect of testosterone therapy on pelvic floor muscles in postmenopausal women, 60 years and older, with stress urinary incontinence. The first aim is to compare the efficacy of testosterone supplementation versus placebo on the volume of levator ani muscles of the pelvic floor, assessed by magnetic resonance imaging (MRI). The second aim is to assess the efficacy of testosterone supplementation in improving indices of urodynamic function (i.e., bladder, urethra, and sphincter function), assessed by urodynamic testing. These urodynamic measures include Valsava leak point pressure, urethral pressure profile, cystometry and electromyography. As an exploratory aim, the efficacy of testosterone treatment relative to placebo will be assessed using self-reported urinary symptoms assessed by the Urogenital Distress Inventory (UDI) and quality of life assessed by the Incontinence Impact Questionnaire (IIQ).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medically documented urge or mixed urinary incontinence (stress and urge) on physical exam or urodynamic testing.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Testosterone Cypionate 25-mg weekly by intramuscular injection
Drug: Testosterone cypionate
Placebo intramuscular injections weekly
Drug: Placebo
weekly by intramuscular injection
weekly by intramuscular injection
Change in pelvic floor muscle volume
volume of levator ani muscles of the pelvic floor, assessed by magnetic resonance imaging (MRI)
Time frame: 12 weeks
Change in abdominal leak point pressure
abdominal leak point pressure will be measured by a urodynamic function study
Time frame: 12 weeks
Change in urine flow rate
urine flow rate will be measured by urodynamic function a study
Time frame: 12 weeks
Change in bladder pressure
bladder pressure will be measured during filling, storage and voiding by urodynamic study
Time frame: 12 weeks
Change in post void residual urine volume
post void residual urine volume will be measured using bladder ultrasound
Time frame: 12 weeks
Change in urinary symptoms
self-reported urinary symptoms will be assessed by the Urogenital Distress Inventory (UDI). Total score ranges from 6-24 with higher scores indicating higher severity of symptoms
Time frame: 12 weeks
Change in quality of life
quality of life will be assessed by the Incontinence Impact Questionnaire (IIQ). Total score ranges from 0-21 with higher scores indicating worse impact on quality of life.
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.
Of 15 phase 2 interventional studies under Urinary Incontinence, Stress, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's planned 22 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Testosterone 17 beta-cypionate
Urinary Incontinence, Stress →
Brigham and Women's Hospital →